文献速递白血病造血干细胞移植与细胞治疗

环磷酰胺与依托泊苷联合全身照射作为成人Ph阴性急性淋巴细胞白血病异基因干细胞移植预处理方案的比较:代表欧洲血液与骨髓移植学会ALWP

Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation.
PubMed 文献 · Am J Hematol · 2018-03-30

该回顾性研究比较了环磷酰胺联合全身照射(Cy/TBI)与依托泊苷联合全身照射(Vp/TBI)预处理方案在成人Ph阴性急性淋巴细胞白血病异基因造血干细胞移植中的效果。纳入第一次或第二次完全缓解期接受移植的患者,Cy/TBI组1346例,Vp/TBI组152例。单因素分析显示Vp/TBI组5年复发率降低(17% vs 30%,P=0.007)、无白血病生存率提高(60% vs 50%,P=0.04)、GVHD与无复发生存率提高(43% vs 33%,P=0.04);多因素分析显示Vp/TBI与复发风险降低相关(HR=0.62,P=0.04),其他终点无显著差异。

要点

  • Vp/TBI组5年复发率17% vs Cy/TBI组30%(P=0.007),Vp/TBI组较低。
  • Vp/TBI组5年无白血病生存率60% vs Cy/TBI组50%(P=0.04),Vp/TBI组较高。
  • 多因素分析Vp/TBI与复发风险降低相关(HR=0.62,P=0.04),其他终点无显著差异。

核心结论

  • 对于接受异基因造血干细胞移植的成人Ph阴性急性淋巴细胞白血病患者,基于依托泊苷联合全身照射的预处理方案在疾病控制方面似乎比环磷酰胺联合全身照射更有效。

研究设计与样本

  • 回顾性比较研究,纳入第一次或第二次完全缓解期接受异基因造血干细胞移植的成人Ph阴性急性淋巴细胞白血病患者,Cy/TBI组1346例,Vp/TBI组152例。

主要发现

  • 单因素分析:Vp/TBI组5年复发率17% vs Cy/TBI组30%(P=0.007),Vp/TBI组较低。
  • 单因素分析:Vp/TBI组5年无白血病生存率60% vs Cy/TBI组50%(P=0.04),Vp/TBI组较高。
  • 单因素分析:Vp/TBI组5年GVHD与无复发生存率43% vs Cy/TBI组33%(P=0.04),Vp/TBI组较高。
  • 非复发死亡率及急慢性GVHD发生率无显著差异。
  • 多因素分析:Vp/TBI与复发风险降低相关(HR=0.62,P=0.04),其他研究终点无显著差异。

关键数值与推荐

  • 5年复发率:Vp/TBI组17% vs Cy/TBI组30%(P=0.007)。
  • 5年无白血病生存率:Vp/TBI组60% vs Cy/TBI组50%(P=0.04)。
  • 5年GVHD与无复发生存率:Vp/TBI组43% vs Cy/TBI组33%(P=0.04)。
  • 多因素分析复发风险:Vp/TBI vs Cy/TBI的HR=0.62(P=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic cell transplantation (alloHCT) with myeloablative conditioning based on total body irradiation (TBI) is widely used for the treatment of adults with acute lymphoblastic leukemia (ALL). TBI is most frequently administered in combination with either cyclophosphamide (Cy/TBI) or etoposide (Vp/TBI). The goal of this study was to retrospectively compare these two regimens. Adult patients with Ph-negative ALL treated with alloHCT in first or second complete remission who received Cy/TBI (n = 1346) or Vp/TBI (n = 152) conditioning were included in the analysis. In a univariate analysis, as compared to Cy/TBI, the use of Vp/TBI was associated with reduced incidence of relapse (17% vs. 30% at 5 years, P = .007), increased rate of leukemia-free survival (60% vs. 50%, P = .04), and improved "graft versus host disease (GVHD) and relapse-free survival" (GRFS, 43% vs. 33%, P = .04). No significant effect could be observed in terms of the incidence of nonrelapse mortality or acute or chronic GVHD. In a multivariate model, the use of Vp/TBI was associated with reduced risk of relapse (HR = 0.62, P = .04) while the effect on other study end-points was not significant. In conclusion, conditioning regimen based on Vp combined with TBI appears more effective for disease control than the combination of Cy with TBI for adult patients with Ph-negative ALL treated with alloHCT.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Czyz A, Labopin M, Giebel S, et al. Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2018. PMID: 29574915. doi:10.1002/ajh.25091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。